Postbiotics as potential new therapeutic agents for sepsis

Xiran Lou; Jinfang Xue; Ruifei Shao; Chunyan Mo; Fuping Wang; Guobing Chen

doi:10.1093/burnst/tkad022

您当前的位置：

首页 >

文章列表页 >

Postbiotics as potential new therapeutic agents for sepsis

更新时间：2023-08-29

- Postbiotics as potential new therapeutic agents for sepsis
- Postbiotics as potential new therapeutic agents for sepsis
- Burns & Trauma 2023年11卷第1期
- 作者机构：
  
  1. Medical School, Kunming University of Science and Technology
  2. Department of Emergency Medicine, The First People's Hospital of Yunnan Province
- 作者简介：
- 基金信息：
  
  This study was supported by the National Natural Science Foundation of China (No. 82160366), Yunnan Young and Middle-aged Academic and Technical Leaders Reserve Talent Project (No. C098-2060499), Yunnan Clinical Medical Center Open Project (No. 2021LCZXXF-HX03) and Yunnan Key Laboratory of Stomatology Open Project (No. 2022YNKQ004).
- DOI：10.1093/burnst/tkad022
  中图分类号：
- 纸质出版日期：2023，
  
  网络出版日期：2023-6-15，
扫描看全文
Xiran Lou, Jinfang Xue, Ruifei Shao, 等. Postbiotics as potential new therapeutic agents for sepsis[J]. Burns & Trauma, 2023,11(1).

Xiran Lou, Jinfang Xue, Ruifei Shao, Chunyan Mo, Fuping Wang, Guobing Chen, Postbiotics as potential new therapeutic agents for sepsis, Burns & Trauma, Volume 11, 2023, tkad022, https://doi.org/10.1093/burnst/tkad022
Xiran Lou, Jinfang Xue, Ruifei Shao, 等. Postbiotics as potential new therapeutic agents for sepsis[J]. Burns & Trauma, 2023,11(1). DOI： 10.1093/burnst/tkad022.

Xiran Lou, Jinfang Xue, Ruifei Shao, Chunyan Mo, Fuping Wang, Guobing Chen, Postbiotics as potential new therapeutic agents for sepsis, Burns & Trauma, Volume 11, 2023, tkad022, https://doi.org/10.1093/burnst/tkad022 DOI：

摘要

Abstract

Sepsis is the main cause of death in critically ill patients and gut microbiota dysbiosis plays a crucial role in sepsis. On the one hand

sepsis leads to the destruction of gut microbiota and induces and aggravates terminal organ dysfunction. On the other hand

the activation of pathogenic gut flora and the reduction in beneficial microbial products increase the susceptibility of the host to sepsis. Although probiotics or fecal microbiota transplantation preserve gut barrier function on multiple levels

their efficacy in sepsis with intestinal microbiota disruptions remains uncertain. Postbiotics consist of inactivated microbial cells or cell components. They possess antimicrobial

immunomodulatory

antioxidant and antiproliferative activities. Microbiota-targeted therapy strategies

such as postbiotics

may reduce the incidence of sepsis and improve the prognosis of patients with sepsis by regulating gut microbial metabolites

improving intestinal barrier integrity and changing the composition of the gut microbiota. They offer a variety of mechanisms and might even be superior to more conventional ‘biotics’ such as probiotics and prebiotics. In this review

we present an overview of the concept of postbiotics and summarize what is currently known about postbiotics and their prospective utility in sepsis therapy. Overall

postbiotics show promise as a viable adjunctive therapy option for sepsis.

关键词

Keywords

SepsisGut microbiotaDysbiosisPostbiotics

references

1.Adak A, Khan MR. An insight into gut microbiota and its functionalities. Cell Mol Life Sci. 2019;76:473–93.

2.Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms. 2019;7:14.

3.Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature. 2011;473:174–80.

4.Szychowiak P, Villageois-Tran K, Patrier J, Timsit JF, Ruppé É. The role of the microbiota in the management of intensive care patients. Ann Intensive Care. 2022;12:3.

5.Hiippala K, Jouhten H, Ronkainen A, Hartikainen A, Kainulainen V, Jalanka J, et al. The potential of gut commensals in reinforcing intestinal barrier function and alleviating inflammation. Nutrients. 2018;10:988.

6.Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801–10.

7.Fleischmann C, Scherag A, Adhikari NK, Hartog CS, Tsaganos T, Schlattmann P, et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med. 2016;193:259–72.

8.Moron R, Galvez J, Colmenero M, Anderson P, Cabeza J, Rodriguez-Cabezas ME. The importance of the microbiome in critically ill patients: role of nutrition. Nutrients. 2019;11:3002.

9.Maguire M, Maguire G. Gut dysbiosis, leaky gut, and intestinal epithelial proliferation in neurological disorders: towards the development of a new therapeutic using amino acids, prebiotics, probiotics, and postbiotics. Rev Neurosci. 2019;30:179–201.

10.Salminen S, Collado MC, Endo A, Hill C, Lebeer S, Quigley EMM, et al. The international scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat Rev Gastroenterol Hepatol. 2021;18:649–67.

11.Mayorgas A, Dotti I, Salas A. Microbial metabolites, Postbiotics, and intestinal epithelial function. Mol Nutr Food Res. 2021;65:e2000188.

12.Lou X, Xue J, Shao R, Yang Y, Ning D, Mo C, et al. Fecal microbiota transplantation and short-chain fatty acids reduce sepsis mortality by remodeling antibiotic-induced gut microbiota disturbances. Front Immunol. 2022;13:1063543.

13.Miller WD, Keskey R, Alverdy JC. Sepsis and the microbiome: a vicious cycle. J Infect Dis. 2021;223:S264–s269.

14.Dickson RP. The microbiome and critical illness. Lancet Respir Med. 2016;4:59–72.

15.Song JH, Kim YS. Recurrent Clostridium difficile infection: risk factors, treatment, and prevention. Gut Liver. 2019;13:16–24.

16.Ravi A, Halstead FD, Bamford A, Casey A, Thomson NM, van Schaik W, et al. Loss of microbial diversity and pathogen domination of the gut microbiota in critically ill patients. Microb Genom. 2019;5:e000293.

17.Im Y, Kang D, Ko RE, Lee YJ, Lim SY, Park S, et al. Time-to-antibiotics and clinical outcomes in patients with sepsis and septic shock: a prospective nationwide multicenter cohort study. Crit Care. 2022;26:19.

18.Taur Y, Xavier JB, Lipuma L, Ubeda C, Goldberg J, Gobourne A, et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2012;55:905–14.

19.Prescott HC, Dickson RP, Rogers MA, Langa KM, Iwashyna TJ. Hospitalization type and subsequent severe sepsis. Am J Respir Crit Care Med. 2015;192:581–8.

20.Panpetch W, Somboonna N, Bulan DE, Issara-Amphorn J, Worasilchai N, Finkelman M, et al. Gastrointestinal colonization of Candida Albicans increases serum (1→3)-β-D-Glucan, without Candidemia, and worsens Cecal ligation and puncture sepsis in murine model. Shock. 2018;49:62–70.

21.Chen G, Huang B, Fu S, Li B, Ran X, He D, et al. G protein-coupled receptor 109A and host microbiota modulate intestinal epithelial integrity during sepsis. Front Immunol. 2018;9:2079.

22.Garcia ER, Vergara A, Aziz F, Narváez S, Cuesta G, Hernández M, et al. Changes in the gut microbiota and risk of colonization by multidrug-resistant bacteria, infection, and death in critical care patients. Clin Microbiol Infect. 2022;28:975–82.

23.Adelman MW, Woodworth MH, Langelier C, Busch LM, Kempker JA, Kraft CS, et al. The gut microbiome's role in the development, maintenance, and outcomes of sepsis. Crit Care. 2020;24:278.

24.Bassetti M, Bandera A, Gori A. Therapeutic potential of the gut microbiota in the Management of Sepsis. Crit Care. 2020;24:105.

25.Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document. The international scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11:506–14.

26.Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, et al. Expert consensus document: the international scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017;14:491–502.

27.Davani-Davari D, Negahdaripour M, Karimzadeh I, Seifan M, Mohkam M, Masoumi SJ, et al. Prebiotics: definition, types, sources, mechanisms, and clinical applications. Foods. 2019;8:92.

28.Swanson KS, Gibson GR, Hutkins R, Reimer RA, Reid G, Verbeke K, et al. The international scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. Nat Rev Gastroenterol Hepatol. 2020;17:687–701.

29.Markowiak P, Śliżewska K. Effects of probiotics, prebiotics, and Synbiotics on human health. Nutrients. 2017;9:1021.

30.Rao SC, Athalye-Jape GK, Deshpande GC, Simmer KN, Patole SK. Probiotic supplementation and late-onset sepsis in preterm infants: a meta-analysis. Pediatrics. 2016;137:e20153684.

31.Chen L, Li H, Chen Y, Yang Y. Probiotic lactobacillus rhamnosus GG reduces mortality of septic mice by modulating gut microbiota composition and metabolic profiles. Nutrition. 2020;78:e000293.

32.Panigrahi P, Parida S, Nanda NC, Satpathy R, Pradhan L, Chandel DS, et al. A randomized synbiotic trial to prevent sepsis among infants in rural India. Nature. 2017;548:407–12.

33.Wang K, Zeng Q, Li KX, Wang Y, Wang L, Sun MW, et al. Efficacy of probiotics or synbiotics for critically ill adult patients: a systematic review and meta-analysis of randomized controlled trials. Burns. Dent Traumatol. 2022;10:tkac004.

34.Colautti A, Arnoldi M, Comi G, Iacumin L. Antibiotic resistance and virulence factors in lactobacilli: something to carefully consider. Food Microbiol. 2022;103:103934.

35.Katkowska M, Garbacz K, Kusiak A. Probiotics: should all patients take them? Microorganisms. 2021;9:2620.

36.Barraud D, Blard C, Hein F, Marçon O, Cravoisy A, Nace L, et al. Probiotics in the critically ill patient: a double blind, randomized, placebo-controlled trial. Intensive Care Med. 2010;36:1540–7.

37.Besselink MG, van Santvoort HC, Renooij W, de Smet MB, Boermeester MA, Fischer K, et al. Intestinal barrier dysfunction in a randomized trial of a specific probiotic composition in acute pancreatitis. Ann Surg. 2009;250:712–9.

38.Johnstone J, Meade M, Lauzier F, Marshall J, Duan E, Dionne J, et al. Effect of probiotics on incident ventilator-associated pneumonia in critically ill patients: a randomized clinical trial. JAMA. 2021;326:1024–33.

39.Tsilingiri K, Rescigno M. Postbiotics: what else? Benef Microbes. 2013;4:101–7.

40.Nataraj BH, Ali SA, Behare PV, Yadav H. Postbiotics-parabiotics: the new horizons in microbial biotherapy and functional foods. Microb Cell Factories. 2020;19:168.

41.Żółkiewicz J, Marzec A, Ruszczyński M, Feleszko W. Postbiotics-a step beyond pre- and probiotics. Nutrients. 2020;12:2189.

42.Wegh CAM, Geerlings SY, Knol J, Roeselers G, Belzer C. Postbiotics and their potential applications in early life nutrition and beyond. Int J Mol Sci. 2019;20:4673.

43.Patel RM, Denning PW. Therapeutic use of prebiotics, probiotics, and postbiotics to prevent necrotizing enterocolitis: what is the current evidence? Clin Perinatol. 2013;40:11–25.

44.Sharma M, Shukla G. Metabiotics: one step ahead of probiotics; an insight into mechanisms involved in Anticancerous effect in colorectal cancer. Front Microbiol. 2016;7:1940.

45.Mack I, Schwille-Kiuntke J, Mazurak N, Niesler B, Zimmermann K, Mönnikes H, et al. A nonviable probiotic in irritable bowel syndrome: a randomized, double-blind, placebo-controlled. Multicenter Study Clin Gastroenterol Hepatol. 2022;20:1039–1047.e9.

46.Andresen V, Gschossmann J, Layer P. Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial. Lancet Gastroenterol Hepatol. 2020;5:658–66.

47.Canducci F, Armuzzi A, Cremonini F, Cammarota G, Bartolozzi F, Pola P, et al. A lyophilized and inactivated culture of lactobacillus acidophilus increases helicobacter pylori eradication rates. Aliment Pharmacol Ther. 2000;14:1625–9.

48.Yang C, Liang L, Lv P, Liu L, Wang S, Wang Z, et al. Effects of non-viable lactobacillus reuteri combining with 14-day standard triple therapy on helicobacter pylori eradication: a randomized double-blind placebo-controlled trial. Helicobacter. 2021;26:e12856.

49.Rather IA, Kim BC, Lew LC, Cha SK, Lee JH, Nam GJ, et al. Oral Administration of Live and Dead Cells of lactobacillus sakei proBio65 alleviated atopic dermatitis in children and adolescents: a randomized, double-blind, and placebo-controlled study. Probiotics Antimicrob Proteins. 2021;13:315–26.

50.Jeong K, Kim M, Jeon SA, Kim YH, Lee S. A randomized trial of lactobacillus rhamnosus IDCC 3201 tyndallizate (RHT3201) for treating atopic dermatitis. Pediatr Allergy Immunol. 2020;31:783–92.

51.D'Auria E, Panelli S, Lunardon L, Pajoro M, Paradiso L, Beretta S, et al. Rice flour fermented with lactobacillus paracasei CBA L74 in the treatment of atopic dermatitis in infants: a randomized, double- blind, placebo- controlled trial. Pharmacol Res. 2021;163:105284.

52.Braido F, Melioli G, Cazzola M, Fabbri L, Blasi F, Moretta L, et al. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: a multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: advanced immunological approach in COPD exacerbation). Pulm Pharmacol Ther. 2015;33:75–80.

53.Tandon MK, Phillips M, Waterer G, Dunkley M, Comans P, Clancy R. Oral immunotherapy with inactivated nontypeable haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest. 2010;137:805–11.

54.Montané E, Barriocanal AM, Arellano AL, Valderrama A, Sanz Y, Perez-Alvarez N, et al. Pilot, double-blind, randomized, placebo-controlled clinical trial of the supplement food Nyaditum resae® in adults with or without latent TB infection: safety and immunogenicity. PLoS One. 2017;12:e0171294.

55.Zagólski O, Stręk P, Kasprowicz A, Białecka A. Effectiveness of polyvalent bacterial lysate and autovaccines against upper respiratory tract bacterial colonization by potential pathogens: a randomized study. Med Sci Monit. 2015;21:2997–3002.

56.Braido F, Melioli G, Candoli P, Cavalot A, Di Gioacchino M, Ferrero V, et al. The bacterial lysate Lantigen B reduces the number of acute episodes in patients with recurrent infections of the respiratory tract: the results of a double blind, placebo controlled, multicenter clinical trial. Immunol Lett. 2014;162:185–93.

57.Sawada D, Sugawara T, Hirota T, Nakamura Y. Effects of lactobacillus gasseri CP2305 on mild menopausal symptoms in middle-aged women. Nutrients. 2022;14:1695.

58.Takaragawa M, Sakuraba K, Suzuki Y. Heat-killed Lactococcus lactis subsp. cremoris H61 altered the iron status of young women: a randomized, double-blinded, placebo-controlled, parallel-group comparative study. Nutrients. 2022;14:3144.

59.Companys J, Calderón-Pérez L, Pla-Pagà L, Llauradó E, Sandoval-Ramirez BA, Gosalbes MJ, et al. Effects of enriched seafood sticks (heat-inactivated B. animalis subsp. lactis CECT 8145, inulin, omega-3) on cardiometabolic risk factors and gut microbiota in abdominally obese subjects: randomized controlled trial. Eur J Nutr. 2022;61:3597–611.

60.Singh A, D'Amico D, Andreux PA, Fouassier AM, Blanco-Bose W, Evans M, et al. Urolithin a improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Rep Med. 2022;3:100633.

61.Tarrerias AL, Costil V, Vicari F, Létard JC, Adenis-Lamarre P, Aisène A, et al. The effect of inactivated lactobacillus LB fermented culture medium on symptom severity: observational investigation in 297 patients with diarrhea-predominant irritable bowel syndrome. Dig Dis. 2011;29:588–91.

62.Jones C, Badger SA, Regan M, Clements BW, Diamond T, Parks RW, et al. Modulation of gut barrier function in patients with obstructive jaundice using probiotic LP299v. Eur J Gastroenterol Hepatol. 2013;25:1424–30.

63.Xiao SD, Zhang DZ, Lu H, Jiang SH, Liu HY, Wang GS, et al. Multicenter, randomized, controlled trial of heat-killed lactobacillus acidophilus LB in patients with chronic diarrhea. Adv Ther. 2003;20:253–60.

64.Zhang J, Guo S, Li C, Jiang X. Therapeutic effects of inhaled inactivated mycobacterium phlei in adult patients with moderate persistent asthma. Immunotherapy. 2012;4:383–7.

65.Rhys-Jones D, Climie RE, Gill PA, Jama HA, Head GA, Gibson PR, et al. Microbial interventions to control and reduce blood pressure in Australia (MICRoBIA): rationale and design of a double-blinded randomised cross-over placebo controlled trial. Trials. 2021;22:496.

66.Nishida K, Sawada D, Kuwano Y, Tanaka H, Rokutan K. Health benefits of lactobacillus gasseri CP2305 tablets in young adults exposed to chronic stress: a randomized, double-blind, placebo-controlled study. Nutrients. 2019;11:1859.

67.Hoffman JR, Hoffman MW, Zelicha H, Gepner Y, Willoughby DS, Feinstein U, et al. The effect of 2 weeks of inactivated probiotic Bacillus coagulans on endocrine, inflammatory, and performance responses during self-Defense training in soldiers. J Strength Cond Res. 2019;33:2330–7.

68.Nishida K, Sawada D, Kawai T, Kuwano Y, Fujiwara S, Rokutan K. Para-psychobiotic lactobacillus gasseri CP2305 ameliorates stress-related symptoms and sleep quality. J Appl Microbiol. 2017;123:1561–70.

69.van der Hee B, Wells JM. Microbial regulation of host physiology by short-chain fatty acids. Trends Microbiol. 2021;29:700–12.

70.Kimura I, Ichimura A, Ohue-Kitano R, Igarashi M. Free fatty acid receptors in health and disease. Physiol Rev. 2020;100:171–210.

71.Xu R, Ding Z, Zhao P, Tang L, Tang X, Xiao S. The effects of early post-operative soluble dietary Fiber enteral nutrition for colon cancer. Nutrients. 2016;8:584.

72.Chen T, Ma Y, Xu L, Sun C, Xu H, Zhu J. Soluble dietary Fiber reduces feeding intolerance in severe acute pancreatitis: a randomized study. JPEN J Parenter Enteral Nutr. 2021;45:125–35.

73.Cara KC, Beauchesne AR, Wallace TC, Chung M. Safety of using enteral nutrition formulations containing dietary Fiber in hospitalized critical care patients: a systematic review and meta-analysis. JPEN J Parenter Enteral Nutr. 2021;45:882–906.

74.Kaewdech A, Sripongpun P, Wetwittayakhlang P, Churuangsuk C. The effect of fiber supplementation on the prevention of diarrhea in hospitalized patients receiving enteral nutrition: a meta-analysis of randomized controlled trials with the GRADE assessment. Front Nutr. 2022;9:1008464.

75.Zhang F, Wan Y, Zuo T, Yeoh YK, Liu Q, Zhang L, et al. Prolonged impairment of short-chain fatty acid and L-isoleucine biosynthesis in gut microbiome in patients with COVID-19. Gastroenterology. 2022;162:548–561.e4.

76.Shimizu K, Yamada T, Ogura H, Mohri T, Kiguchi T, Fujimi S, et al. Synbiotics modulate gut microbiota and reduce enteritis and ventilator-associated pneumonia in patients with sepsis: a randomized controlled trial. Crit Care. 2018;22:239.

77.Liao H, Li H, Bao H, Jiang L, Du J, Guo Y, et al. Short chain fatty acids protect the cognitive function of sepsis associated encephalopathy mice via GPR43. Front Neurol. 2022;13:909436.

78.Wang F, Liu J, Weng T, Shen K, Chen Z, Yu Y, et al. The inflammation induced by lipopolysaccharide can be mitigated by short-chain fatty acid, butyrate, through upregulation of IL-10 in septic shock. Scand J Immunol. 2017;85:258–63.

79.Okumura T, Nozu T, Ishioh M, Igarashi S, Kumei S, Ohhira M. Centrally administered butyrate improves gut barrier function, visceral sensation and septic lethality in rats. J Pharmacol Sci. 2021;146:183–91.

80.Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. The role of short-chain fatty acids in health and disease. Adv Immunol. 2014;121:91–119.

81.Abanoz HS, Kunduhoglu B. Antimicrobial activity of a Bacteriocin produced by enterococcus faecalis KT11 against some pathogens and antibiotic-resistant bacteria. Korean J Food Sci Anim Resour. 2018;38:1064–79.

82.Heilbronner S, Krismer B, Brötz-Oesterhelt H, Peschel A. The microbiome-shaping roles of bacteriocins. Nat Rev Microbiol. 2021;19:726–39.

83.Behrens HM, Six A, Walker D, Kleanthous C. The therapeutic potential of bacteriocins as protein antibiotics. Emerg Top Life Sci. 2017;1:65–74.

84.Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the global burden of disease study. Lancet. 2020;395:200–11.

85.Liu S, Deng S, Liu H, Tang L, Wang M, Xin B, et al. Four novel leaderless Bacteriocins, Bacin A1, A2, A3, and A4 exhibit potent antimicrobial and Antibiofilm activities against methicillin-resistant Staphylococcus aureus. Microbiol Spectr. 2022;10:e0094522.

86.Wang S, Wang Q, Zeng X, Ye Q, Huang S, Yu H, et al. Use of the antimicrobial peptide Sublancin with combined antibacterial and immunomodulatory activities to protect against methicillin-resistant Staphylococcus aureus infection in mice. J Agric Food Chem. 2017;65:8595–605.

87.Gillor O, Etzion A, Riley MA. The dual role of bacteriocins as anti- and probiotics. Appl Microbiol Biotechnol. 2008;81:591–606.

88.Wang T, Wang S, Dong S, Zhang Y, Ismael M, Wang S, et al. Interaction of Companilactobacillus crustorum MN047-derived bacteriocins with gut microbiota. Food Chem. 2022;396:133730.

89.Meng F, Liu Y, Nie T, Tang C, Lyu F, Bie X, et al. Plantaricin a, derived from Lactiplantibacillus plantarum, reduces the intrinsic resistance of gram-negative bacteria to hydrophobic antibiotics. Appl Environ Microbiol. 2022;88:e0037122.

90.van Beilen JB, Li Z. Enzyme technology: an overview. Curr Opin Biotechnol. 2002;13:338–44.

91.García-Cano I, Rocha-Mendoza D, Kosmerl E, Zhang L, Jiménez-Flores R. Technically relevant enzymes and proteins produced by LAB suitable for industrial and biological activity. Appl Microbiol Biotechnol. 2020;104:1401–22.

92.Maske BL, de Melo Pereira GV, da , et al. A review on enzyme-producing lactobacilli associated with the human digestive process: from metabolism to application. Enzym Microb Technol. 2021;149:109836.

93.Chandanwale A, Langade D, Sonawane D, Gavai P. A randomized, clinical trial to evaluate efficacy and tolerability of trypsin:chymotrypsin as compared to Serratiopeptidase and trypsin:bromelain:Rutoside in wound management. Adv Ther. 2017;34:180–98.

94.Shah D, Mital K. The role of trypsin:chymotrypsin in tissue repair. Adv Ther. 2018;35:31–42.

95.Asakura H, Asamura R, Ontachi Y, Hayashi T, Omote M, Arahata M, et al. Beneficial effects of urokinase on lipopolysaccharide-induced disseminated intravascular coagulation in rats: focus on organ function and endothelin levels. Thromb Haemost. 2005;93:724–8.

96.Yang J, Zhang R, Zhao H, Qi H, Li J, Li JF, et al. Bioinspired copper single-atom nanozyme as a superoxide dismutase-like antioxidant for sepsis treatment. In: Exploration.Wiley Online Library, 2022;2:20210267.

97.Bao W, Xing H, Cao S, Long X, Liu H, Ma J, et al. Neutrophils restrain sepsis associated coagulopathy via extracellular vesicles carrying superoxide dismutase 2 in a murine model of lipopolysaccharide induced sepsis. Nat Commun. 2022;13:4583.

98.Constantino L, Galant LS, Vuolo F, Guarido KL, Kist LW, de Oliveira GMT, et al. Extracellular superoxide dismutase is necessary to maintain renal blood flow during sepsis development. Intensive Care Med Exp. 2017;5:15.

99.Uebanso T, Shimohata T, Mawatari K, Takahashi A. Functional roles of B-vitamins in the gut and gut microbiome. Mol Nutr Food Res. 2020;64:e2000426.

100.Calder PC, Ortega EF, Meydani SN, Adkins Y, Stephensen CB, Thompson B, et al. Nutrition, Immunosenescence, and infectious disease: an overview of the scientific evidence on micronutrients and on modulation of the gut microbiota. Adv Nutr. 2022;13:S1–s26.

101.Fowler AA, 3rd, Truwit JD, Hite RD, Morris PE, DeWilde C, Priday A, et al. Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: the CITRIS-ALI randomized clinical trial. JAMA. 2019;322:1261–70.

102.Wang Y, Shi C, Yang Z, Chen F, Gao L. Vitamin D deficiency and clinical outcomes related to septic shock in children with critical illness: a systematic review. Eur J Clin Nutr. 2019;73:1095–101.

103.Moskowitz A, Huang DT, Hou PC, Gong J, Doshi PB, Grossestreuer AV, et al. Effect of ascorbic acid, corticosteroids, and thiamine on organ injury in septic shock: the ACTS randomized clinical trial. JAMA. 2020;324:642–50.

104.Consoli DC, Jesse JJ, Klimo KR, Tienda AA, Putz ND, Bastarache JA, et al. A Cecal slurry mouse model of sepsis leads to acute consumption of vitamin C in the brain. Nutrients. 2020;12:911.

105.Kim SR, Ha YM, Kim YM, Park EJ, Kim JW, Park SW, et al. Ascorbic acid reduces HMGB1 secretion in lipopolysaccharide-activated RAW 264.7 cells and improves survival rate in septic mice by activation of Nrf2/HO-1 signals. Biochem Pharmacol. 2015;95:279–89.

106.Hu Z, Murakami T, Suzuki K, Tamura H, Kuwahara-Arai K, Iba T, et al. Antimicrobial cathelicidin peptide LL-37 inhibits the LPS/ATP-induced pyroptosis of macrophages by dual mechanism. PLoS One. 2014;9:e85765.

107.Suzuki K, Murakami T, Kuwahara-Arai K, Tamura H, Hiramatsu K, Nagaoka I. Human anti-microbial cathelicidin peptide LL-37 suppresses the LPS-induced apoptosis of endothelial cells. Int Immunol. 2011;23:185–93.

108.Belsky JB, Wira CR, Jacob V, Sather JE, Lee PJ. A review of micronutrients in sepsis: the role of thiamine, l-carnitine, vitamin C, selenium and vitamin D. Nutr Res Rev. 2018;31:281–90.

109.Venkatram S, Chilimuri S, Adrish M, Salako A, Patel M, Diaz-Fuentes G. Vitamin D deficiency is associated with mortality in the medical intensive care unit. Crit Care. 2011;15:R292.

110.Wang Y, Yang Z, Gao L, Cao Z, Wang Q. Effects of a single dose of vitamin D in septic children: a randomized, double-blinded, controlled trial. J Int Med Res. 2020;48:300060520926890.

111.Antignac A, Rousselle JC, Namane A, Labigne A, Taha MK, Boneca IG. Detailed structural analysis of the peptidoglycan of the human pathogen Neisseria meningitidis. J Biol Chem. 2003;278:31521–8.

112.Asong J, Wolfert MA, Maiti KK, Miller D, Boons GJ. Binding and cellular activation studies reveal that toll-like receptor 2 can differentially recognize peptidoglycan from gram-positive and gram-negative bacteria. J Biol Chem. 2009;284:8643–53.

113.Wells JM. Immunomodulatory mechanisms of lactobacilli. Microb Cell Factories. 2011;10 Suppl 1:S17.

114.Wu Z, Pan DD, Guo Y, Zeng X. Structure and anti-inflammatory capacity of peptidoglycan from lactobacillus acidophilus in RAW-264.7 cells. Carbohydr Polym. 2013;96:466–73.

115.Wu Z, Pan D, Guo Y, Sun Y, Zeng X. Peptidoglycan diversity and anti-inflammatory capacity in lactobacillus strains. Carbohydr Polym. 2015;128:130–7.

116.Kolling Y, Salva S, Villena J, Alvarez S. Are the immunomodulatory properties of lactobacillus rhamnosus CRL1505 peptidoglycan common for all lactobacilli during respiratory infection in malnourished mice? PLoS One. 2018;13:e0194034.

117.Garbacz K. Anticancer activity of lactic acid bacteria. Semin Cancer Biol. 2022;86:356–66.

118.Griffin ME, Espinosa J, Becker JL, Luo JD, Carroll TS, Jha JK, et al. Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy. Science. 2021;373:1040–6.

119.Khromova NY, Epishkina JM, Karetkin BA, Khabibulina NV, Beloded AV, Shakir IV, et al. The combination of in vitro assessment of stress tolerance ability, autoaggregation, and vitamin B-producing ability for new probiotic strain introduction. Microorganisms. 2022;10:470.

120.Siedler S, Balti R, Neves AR. Bioprotective mechanisms of lactic acid bacteria against fungal spoilage of food. Curr Opin Biotechnol. 2019;56:138–46.

121.De Marco S, Sichetti M, Muradyan D, Piccioni M, Traina G, Pagiotti R, et al. Probiotic cell-free supernatants exhibited anti-inflammatory and antioxidant activity on human gut epithelial cells and macrophages stimulated with LPS. Evid Based Complement Alternat Med. 2018;2018:1756308.

122.Maghsood F, Mirshafiey A, Farahani MM, Modarressi MH, Jafari P, Motevaseli E. Dual effects of cell free supernatants from lactobacillus acidophilus and lactobacillus rhamnosus GG in regulation of MMP-9 by up-regulating TIMP-1 and down-regulating CD147 in PMADifferentiated THP-1 cells. Cell J. 2018;19:559–68.

123.Batista VL, De Jesus LCL, Tavares LM, Barroso FLA, Fernandes L, Freitas ADS, et al. Paraprobiotics and Postbiotics of lactobacillus delbrueckii CIDCA 133 mitigate 5-FU-induced intestinal inflammation. Microorganisms. 2022;10:1418.

124.Kareem KY, Hooi Ling F, Teck Chwen L, May Foong O, Anjas AS. Inhibitory activity of postbiotic produced by strains of lactobacillus plantarum using reconstituted media supplemented with inulin. Gut Pathog. 2014;6:23.

125.Gao J, Li Y, Wan Y, Hu T, Liu L, Yang S, et al. A novel Postbiotic from lactobacillus rhamnosus GG with a beneficial effect on intestinal barrier function. Front Microbiol. 2019;10:477.

126.Zeidan AA, Poulsen VK, Janzen T, Buldo P, Derkx PMF, Øregaard G, et al. Polysaccharide production by lactic acid bacteria: from genes to industrial applications. FEMS Microbiol Rev. 2017;41:S168–s200.

127.Poli A, Anzelmo G, Nicolaus B. Bacterial exopolysaccharides from extreme marine habitats: production, characterization and biological activities. Mar Drugs. 2010;8:1779–802.

128.Castro-Bravo N, Wells JM, Margolles A, Ruas-Madiedo P. Interactions of surface exopolysaccharides from Bifidobacterium and lactobacillus within the intestinal environment. Front Microbiol. 2018;9:2426.

129.Rahbar Saadat Y, Yari Khosroushahi A, Pourghassem GB. A comprehensive review of anticancer, immunomodulatory and health beneficial effects of the lactic acid bacteria exopolysaccharides. Carbohydr Polym. 2019;217:79–89.

130.Liu Z, Zhang Z, Qiu L, Zhang F, Xu X, Wei H, et al. Characterization and bioactivities of the exopolysaccharide from a probiotic strain of lactobacillus plantarum WLPL04. J Dairy Sci. 2017;100:6895–905.

131.Wang J, Wu T, Fang X, Min W, Yang Z. Characterization and immunomodulatory activity of an exopolysaccharide produced by lactobacillus plantarum JLK0142 isolated from fermented dairy tofu. Int J Biol Macromol. 2018;115:985–93.

132.Chen Y, Zhang M, Ren F. A role of exopolysaccharide produced by Streptococcus thermophilus in the intestinal inflammation and mucosal barrier in Caco-2 monolayer and dextran sulphate sodium-induced experimental murine colitis. Molecules. 2019;24:513.

133.Marcial G, Villena J, Faller G, Hensel A, de Valdéz GF. Exopolysaccharide-producing Streptococcus thermophilus CRL1190 reduces the inflammatory response caused by helicobacter pylori. Benef Microbes. 2017;8:451–61.

134.Diao Y, Xin Y, Zhou Y, Li N, Pan X, Qi S, et al. Extracellular polysaccharide from bacillus sp. strain LBP32 prevents LPS-induced inflammation in RAW 264.7 macrophages by inhibiting NF-κB and MAPKs activation and ROS production. Int Immunopharmacol. 2014;18:12–9.

135.Maeda H, Zhu X, Omura K, Suzuki S, Kitamura S. Effects of an exopolysaccharide (kefiran) on lipids, blood pressure, blood glucose, and constipation. Biofactors. 2004;22:197–200.

136.Leung V, Vincent C, Edens TJ, Miller M, Manges AR. Antimicrobial resistance Gene Acquisition and depletion following Fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Infect Dis. 2018;66:456–7.

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

Matrix metalloproteinase-8 regulates dendritic cell tolerance in late polymicrobial sepsis via the nuclear factor kappa-B p65/β-catenin pathway

The m6A reader YTHDF2 alleviates the inflammatory response by inhibiting IL-6R/JAK2/STAT1 pathway-mediated high-mobility group box-1 release

p53 promotes the expansion of regulatory T cells via DNMT3a- and TET2- mediated Foxp3 expression in sepsis